FM8 844
e u r o p e a n u r o l o g y , vo l . 7 1 , n o . 5 , Ma y 2 0 1 7
740
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathR. Na, S.L. Zheng, M. Han, H. Yu, D. Jiang, S. Shah, C.M. Ewing, L. Zhang, K. Novakovic,
J. Petkewicz, K. Gulukota, D.L. Helseth Jr, M. Quinn, E. Humphries, K.E. Wiley, S.D. Isaacs, Y. Wu,
X. Liu, N. Zhang, C.-H. Wang, J. Khandekar, P.J. Hulick, D.H. Shevrin, K.A. Cooney, Z. Shen,
A.W. Partin, H.B. Carter, M.A. Carducci, M.A. Eisenberger, S.R. Denmeade, M. McGuire, P.C. Walsh,
B.T. Helfand, C.B. Brendler, Q. Ding, J. Xu, W.B. Isaacs
The carrier rate of germline
BRCA1/2
and
ATM
mutation was ~5-fold higher in lethal
prostate cancer patients than in localized prostate cancer patients. Mutation carriers
of
BRCA1/2
and
ATM
are associated with earlier age at death and shorter survival
time.
748
The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate CancerD.G. Murphy, G.P. Risbridger, R.G. Bristow, S. Sandhu
750
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesM.S. Leapman, J.E. Cowan, J. Simko, G. Roberge, B.A. Stohr, P.R. Carroll, M.R. Cooperberg
A prognostic Gleason grade grouping system differentiated risk of distant prostate
cancer outcomes, including cancer-specific mortality and metastatic progression, in
a cohort of 10 529 patients across management strategies, including active
surveillance.
760
Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based DataJ. He, P.C. Albertsen, D. Moore, D. Rotter, K. Demissie, G. Lu-Yao
Our study used patients identified from 18 US cancer registries to validate a proposed
five-tiered Gleason grade grouping (GGG) system. This is the first study to show that
the five-tiered GGG system predicts prostate cancer–specific mortality well.
764
Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded SpecimensJ.I. Epstein
766
Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative AnalysisA.U. Kishan, T. Shaikh, P.-C. Wang, R.E. Reiter, J. Said, G. Raghavan, N.G. Nickols, W.J. Aronson,
A. Sadeghi, M. Kamrava, D.J. Demanes, M.L. Steinberg, E.M. Horwitz, P.A. Kupelian, C.R. King
Radiotherapy-based treatments and radical prostatectomy offer equivalent survival
for patients with very aggressive Gleason score 9–10 prostate adenocarcinoma.
Importantly, radiotherapy patients received high-dose radiation with androgen
deprivation therapy, consistent with modern standards of care.
774
Local Therapy for Gleason 9–10 Prostate Cancer: Looking to the FutureW.W. Ludwig, A.E. Ross, P.M. Pierorazio
776
Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune ResponseE.B. Ylitalo, E. Thysell, E. Jernberg, M. Lundholm, S. Crnalic, L. Egevad, P. Stattin, A. Widmark,
A. Bergh, P. Wikström
Bone metastases in men with castration resistant prostate cancer show molecular
heterogeneities of probable importance for patient response to different treatment
modalities.
788
Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?M. Lolkema, R. Debets, R. de Wit